Dayang Biotech disclosed its 2026 interim report. In the first half, it achieved operating revenue of 559 million yuan, up 11.93 percent year on year. Net profit attributable to shareholders of the listed company was 57.47 million yuan, up 13.79 percent year on year. Basic earnings per share were 0.5879 yuan. The company plans to distribute a cash dividend of 3 yuan, tax included, for every 10 shares. During the reporting period, both sales volume and average selling price of potassium carbonate products increased year on year, while the selling price of amprolium hydrochloride rose year on year and continued to maintain full production and full sales.
Zhejiang Dayang Biotech Group CoFirst-half net profit up 13.79% and dividend declared.
